Cost-effectiveness and budget impact analysis of vinflunine used in the treatment of patients with urothelial transitional cell carcinoma resistant to platinum-based regimens

As of now, vinflunine is the only second-line chemotherapy drug showing an advantage over the best maintenance therapy in a Phase IIIrandomized study treating patients with urothelial transitional cell carcinoma. Due to the advent of this drug, it was relevant to make a pharmacoeconomic analysis com...

Full description

Bibliographic Details
Main Authors:	A. Yu. Kulikov, Yu. V. Rybchenko
Format:	Article
Language:	Russian
Published:	ABV-press 2015-06-01
Series:	Onkourologiâ
Subjects:	vinflunine urothelial transitional cell carcinoma chemotherapy best maintenance therapy pharmacoeconomic analysis efficiency analysis years of life saved cost analysis cost-effectiveness analysis budget impact analysis
Online Access:	https://oncourology.abvpress.ru/oncur/article/view/452

id	doaj-254f8a47629c4065b7d552bf45215bba
record_format	Article
spelling	doaj-254f8a47629c4065b7d552bf45215bba2021-07-29T08:41:40ZrusABV-pressOnkourologiâ 1726-97761996-18122015-06-01112404510.17650/1726-9776-2015-11-2-40-45436Cost-effectiveness and budget impact analysis of vinflunine used in the treatment of patients with urothelial transitional cell carcinoma resistant to platinum-based regimensA. Yu. Kulikov0Yu. V. Rybchenko1Department for Organization of Drug Provision and Pharmacoeconomics, I. M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow, Russia; 1, Skladochnaya St, Build. 17, Moscow 127018, RussiaDepartment for Organization of Drug Provision and Pharmacoeconomics, I. M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow, Russia; 1, Skladochnaya St, Build. 17, Moscow 127018, RussiaAs of now, vinflunine is the only second-line chemotherapy drug showing an advantage over the best maintenance therapy in a Phase IIIrandomized study treating patients with urothelial transitional cell carcinoma. Due to the advent of this drug, it was relevant to make a pharmacoeconomic analysis comparing therapy with vinflunine in combination with the best maintenance therapy and the latter only. A budget impact analysis showed that the use of the new drug required additional expenditures. The ICER reflecting the cost of one additional year of life and estimating vinflunine therapy as cost-effective was determined by the results of a cost-effectiveness analysis.https://oncourology.abvpress.ru/oncur/article/view/452vinflunineurothelial transitional cell carcinomachemotherapybest maintenance therapypharmacoeconomic analysisefficiency analysisyears of life savedcost analysiscost-effectiveness analysisbudget impact analysis
collection	DOAJ
language	Russian
format	Article
sources	DOAJ
author	A. Yu. Kulikov Yu. V. Rybchenko
spellingShingle	A. Yu. Kulikov Yu. V. Rybchenko Cost-effectiveness and budget impact analysis of vinflunine used in the treatment of patients with urothelial transitional cell carcinoma resistant to platinum-based regimens Onkourologiâ vinflunine urothelial transitional cell carcinoma chemotherapy best maintenance therapy pharmacoeconomic analysis efficiency analysis years of life saved cost analysis cost-effectiveness analysis budget impact analysis
author_facet	A. Yu. Kulikov Yu. V. Rybchenko
author_sort	A. Yu. Kulikov
title	Cost-effectiveness and budget impact analysis of vinflunine used in the treatment of patients with urothelial transitional cell carcinoma resistant to platinum-based regimens
title_short	Cost-effectiveness and budget impact analysis of vinflunine used in the treatment of patients with urothelial transitional cell carcinoma resistant to platinum-based regimens
title_full	Cost-effectiveness and budget impact analysis of vinflunine used in the treatment of patients with urothelial transitional cell carcinoma resistant to platinum-based regimens
title_fullStr	Cost-effectiveness and budget impact analysis of vinflunine used in the treatment of patients with urothelial transitional cell carcinoma resistant to platinum-based regimens
title_full_unstemmed	Cost-effectiveness and budget impact analysis of vinflunine used in the treatment of patients with urothelial transitional cell carcinoma resistant to platinum-based regimens
title_sort	cost-effectiveness and budget impact analysis of vinflunine used in the treatment of patients with urothelial transitional cell carcinoma resistant to platinum-based regimens
publisher	ABV-press
series	Onkourologiâ
issn	1726-9776 1996-1812
publishDate	2015-06-01
description	As of now, vinflunine is the only second-line chemotherapy drug showing an advantage over the best maintenance therapy in a Phase IIIrandomized study treating patients with urothelial transitional cell carcinoma. Due to the advent of this drug, it was relevant to make a pharmacoeconomic analysis comparing therapy with vinflunine in combination with the best maintenance therapy and the latter only. A budget impact analysis showed that the use of the new drug required additional expenditures. The ICER reflecting the cost of one additional year of life and estimating vinflunine therapy as cost-effective was determined by the results of a cost-effectiveness analysis.
topic	vinflunine urothelial transitional cell carcinoma chemotherapy best maintenance therapy pharmacoeconomic analysis efficiency analysis years of life saved cost analysis cost-effectiveness analysis budget impact analysis
url	https://oncourology.abvpress.ru/oncur/article/view/452
work_keys_str_mv	AT ayukulikov costeffectivenessandbudgetimpactanalysisofvinflunineusedinthetreatmentofpatientswithurothelialtransitionalcellcarcinomaresistanttoplatinumbasedregimens AT yuvrybchenko costeffectivenessandbudgetimpactanalysisofvinflunineusedinthetreatmentofpatientswithurothelialtransitionalcellcarcinomaresistanttoplatinumbasedregimens
_version_	1721252547098836992

Cost-effectiveness and budget impact analysis of vinflunine used in the treatment of patients with urothelial transitional cell carcinoma resistant to platinum-based regimens

Similar Items